Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2002-12-20
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia and South Africa. The aim of this trial is to compare the efficacy and safety of repaglinide plus insulin NPH (insulin Neutral Protamine Hagedorn) with insulin NPH alone in subjects with type 2 diabetes inadequately controlled on repaglinide.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human; Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes

• HbA1c (glycosylated haemoglobin): 7-13% (both inclusive)

• BMI (body mass index) maximum 35 kg/m^2